First Patient Dosed in Ph 1b/2 Trial of SLS009 (GFH009) in R/R PTCL
“SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “We are pleased with the initiation of the Phase Ib/II trial of SLS009 in the underserved PTCL patient population. Collaborating with GenFleet amplifies the potential of our highly selective CDK9 inhibitor in multiple indications and reflects our joint commitment to delivering this groundbreaking treatment to cancer patients globally. While our primary efforts are focused on acute myeloid leukemia (AML) in the United States, we remain fully supportive and deeply involved in the PTCL study and will make further development decisions for this indication as we obtain initial data for this Phase Ib/II study from our partner.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000